NABi, a novel beta-sheet breaker, inhibits A beta aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease
- Authors
- Jang, Ja-Young; Rhim, Hyangshuk; Kang, Seongman
- Issue Date
- 1월-2018
- Publisher
- ELSEVIER SCIENCE BV
- Citation
- BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, v.1862, no.1, pp.71 - 80
- Indexed
- SCIE
SCOPUS
- Journal Title
- BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Volume
- 1862
- Number
- 1
- Start Page
- 71
- End Page
- 80
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/78427
- DOI
- 10.1016/j.bbagen.2017.10.014
- ISSN
- 0304-4165
- Abstract
- Amyloid beta (A beta) aggregates are an important therapeutic target for Alzheimer's disease (AD), a fatal neuro-degenerative disease. To date, AD still remains a big challenge due to no effective treatments. Based on the property that A beta aggregates have the cross-beta-structure, a common structural feature in amyloids, we systemically designed the A beta-aggregation inhibitor that maintains A beta-interacting ability but removes toxic part from SOD1 (superoxide dismutase 1)-G93A. We identified NABi (Natural A beta Binder and A beta-aggregation inhibitor) composed of beta 2-3 strands, a novel breaker of A beta aggregation, which does not self-aggregate and has no cytotoxicity at all. The NABi blocks A beta-fibril formation in vitro and in vivo and prevents neuronal cell death, a hallmark of AD pathogenesis. Such anti-amyloidogenic properties can provide novel strategies for treating AD. Furthermore, our study provides molecular insights into the design of amyloidogenic inhibitors to cure various neurodegenerative and amyloid-associated diseases, as NABi would regulate aggregation of other toxic beta-sheet proteins other than A beta.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.